trending Market Intelligence /marketintelligence/en/news-insights/trending/ex8r8PEtDuWHFrK3yBs_6A2 content esgSubNav
In This List

Johnson & Johnson increases US prices of 2 dozen prescription drugs

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Johnson & Johnson increases US prices of 2 dozen prescription drugs

Johnson & Johnson raised U.S. list prices of about two dozen drugs, including some of its top-selling products, Reuters reported.

According to the report, data from Rx Savings Solutions, which sells software to help employers and health plans choose the least expensive medicines, indicated that most of the increases were between 6% and 7%.

Psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto are now among the hundreds of medicines to undergo price hikes at the start of 2019.

Johnson & Johnson said that although price increases on its medicines will average 4.2% in 2019, it expects to receive a lower net price for the therapies due to rebates and discounts it will negotiate with payers.

New Brunswick, N.J.-based J&J, the world's largest pharmaceutical company, has no plans to hike prices on any more drugs this year, according to spokesman Ernie Knewitz.